1
|
Abstract
Ethnic differences may significantly influence the outcome of psychopharmacological treatment, in terms of prescription, adherence, clinical response, emergence of side effects, as well as pharmacokinetics and pharmacodynamics. The purpose of this review was to explore the available literature in order to provide general suggestions to help clinicians in choosing the best therapeutic option for patients, taking into account ethnicity. Although findings are sometimes controversial, the overall published studies suggest that ethnicities other than Caucasians tend to show a lower response to antidepressants and a reduced compliance. Africans tend to be more prescribed with antipsychotics, probably due to cultural stereotypes, except with clozapine, probably for their chronic benign neutropenia. Asians usually require less antipsychotic dosages than Caucasians. The differential response and side effect profile of antidepressants and antipsychotics have been related to individual intrinsic factors, to genetic make-up, but also to cultural and contextual variables. Interestingly, albeit limited data suggest ethnic-related genetic heterogeneity at the level of the serotonin transporters, the cytochromes and some neuroreceptors. Taken together, no conclusive findings are available about the role and impact of ethnicity in psychopharmacology. One of the main problems is that the majority of the studies in psychopharmacology have been conducted on Caucasians, so that there is an urgent need to have data in other populations. Furthermore, in the era of precision medicine, the role of ethnicity may be also supported by genetic analysis.
Collapse
|
2
|
A chaotic viewpoint-based approach to solve haplotype assembly using hypergraph model. PLoS One 2020; 15:e0241291. [PMID: 33120403 PMCID: PMC7595403 DOI: 10.1371/journal.pone.0241291] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2020] [Accepted: 10/12/2020] [Indexed: 12/30/2022] Open
Abstract
Decreasing the cost of high-throughput DNA sequencing technologies, provides a huge amount of data that enables researchers to determine haplotypes for diploid and polyploid organisms. Although various methods have been developed to reconstruct haplotypes in diploid form, their accuracy is still a challenging task. Also, most of the current methods cannot be applied to polyploid form. In this paper, an iterative method is proposed, which employs hypergraph to reconstruct haplotype. The proposed method by utilizing chaotic viewpoint can enhance the obtained haplotypes. For this purpose, a haplotype set was randomly generated as an initial estimate, and its consistency with the input fragments was described by constructing a weighted hypergraph. Partitioning the hypergraph specifies those positions in the haplotype set that need to be corrected. This procedure is repeated until no further improvement could be achieved. Each element of the finalized haplotype set is mapped to a line by chaos game representation, and a coordinate series is defined based on the position of mapped points. Then, some positions with low qualities can be assessed by applying a local projection. Experimental results on both simulated and real datasets demonstrate that this method outperforms most other approaches, and is promising to perform the haplotype assembly.
Collapse
|
3
|
Zhang H, De T, Zhong Y, Perera MA. The Advantages and Challenges of Diversity in Pharmacogenomics: Can Minority Populations Bring Us Closer to Implementation? Clin Pharmacol Ther 2020; 106:338-349. [PMID: 31038731 DOI: 10.1002/cpt.1491] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2019] [Accepted: 04/18/2019] [Indexed: 01/01/2023]
Abstract
Health disparities exist among minorities in the United States, with differences seen in disease prevalence, mortality, and responses to medications. These differences are multifactorial with genetic variation explaining a portion of this variability. Pharmacogenomics aims to find the effect of genetic variations on drug response, with the goal of optimizing drug therapy and development. Although genome-wide association studies have been useful in unbiasedly surveying the genome for genetic drivers of clinically relevant phenotypes, most of these studies have been conducted in mainly participants of European and Asian descent, contributing to a growing health disparity in precision medicine. Diversity is important to pharmacogenomic studies, and there may be real advantages to the use of these complex genomes in pharmacogenomics. In this review we will outline some of the advantages and confounders of pharmacogenomics in minorities, describe the role of genetic variation in pharmacologic pathways, and highlight a number of population-specific findings.
Collapse
Affiliation(s)
- Honghong Zhang
- Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
| | - Tanima De
- Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
| | - Yizhen Zhong
- Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
| | - Minoli A Perera
- Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
| |
Collapse
|
4
|
Perna G, Alciati A, Daccò S, Grassi M, Caldirola D. Personalized Psychiatry and Depression: The Role of Sociodemographic and Clinical Variables. Psychiatry Investig 2020; 17:193-206. [PMID: 32160691 PMCID: PMC7113177 DOI: 10.30773/pi.2019.0289] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/28/2019] [Accepted: 01/14/2020] [Indexed: 02/06/2023] Open
Abstract
Despite several pharmacological options, the clinical outcomes of major depressive disorder (MDD) are often unsatisfactory. Personalized psychiatry attempts to tailor therapeutic interventions according to each patient's unique profile and characteristics. This approach can be a crucial strategy in improving pharmacological outcomes in MDD and overcoming trial-and-error treatment choices. In this narrative review, we evaluate whether sociodemographic (i.e., gender, age, race/ethnicity, and socioeconomic status) and clinical [i.e., body mass index (BMI), severity of depressive symptoms, and symptom profiles] variables that are easily assessable in clinical practice may help clinicians to optimize the selection of antidepressant treatment for each patient with MDD at the early stages of the disorder. We found that several variables were associated with poorer outcomes for all antidepressants. However, only preliminary associations were found between some clinical variables (i.e., BMI, anhedonia, and MDD with melancholic/atypical features) and possible benefits with some specific antidepressants. Finally, in clinical practice, the assessment of sociodemographic and clinical variables considered in our review can be valuable for early identification of depressed individuals at high risk for poor responses to antidepressants, but there are not enough data on which to ground any reliable selection of specific antidepressant class or compounds. Recent advances in computational resources, such as machine learning techniques, which are able to integrate multiple potential predictors, such as individual/ clinical variables, biomarkers, and genetic factors, may offer future reliable tools to guide personalized antidepressant choice for each patient with MDD.
Collapse
Affiliation(s)
- Giampaolo Perna
- Humanitas University Department of Biomedical Sciences, Milan, Italy.,Department of Clinical Neurosciences, Villa San Benedetto Menni Hospital, Hermanas Hospitalarias, Como, Italy.,Department of Psychiatry and Neuropsychology, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.,Department of Psychiatry and Behavioral Sciences, Leonard Miller School of Medicine, Miami University, Miami, USA
| | - Alessandra Alciati
- Department of Clinical Neurosciences, Villa San Benedetto Menni Hospital, Hermanas Hospitalarias, Como, Italy.,Humanitas Clinical and Research Center, IRCCS, Milan, Italy
| | - Silvia Daccò
- Humanitas University Department of Biomedical Sciences, Milan, Italy.,Department of Clinical Neurosciences, Villa San Benedetto Menni Hospital, Hermanas Hospitalarias, Como, Italy
| | - Massimiliano Grassi
- Humanitas University Department of Biomedical Sciences, Milan, Italy.,Department of Clinical Neurosciences, Villa San Benedetto Menni Hospital, Hermanas Hospitalarias, Como, Italy
| | - Daniela Caldirola
- Humanitas University Department of Biomedical Sciences, Milan, Italy.,Department of Clinical Neurosciences, Villa San Benedetto Menni Hospital, Hermanas Hospitalarias, Como, Italy
| |
Collapse
|
5
|
Abstract
The association between ethnicity and pharmacology has been reported in the medical literature for several decades. However, the relationship between ethnicity and psychopharmacology has become widely recognised only in the last two or three decades. The large-scale migration which started after the Second World War, at first to the USA and more recently to other higher-income countries, as a result of globalisation, has greatly contributed to the attention and focus given to these migrant groups. In this context, these migrant groups primarily comprise ethnic and racial minority groups. This article briefly reviews the relationship between ethnicity and psychopharmacological agents.
Collapse
|
6
|
Lv D, Zhao M, Chen L, Yu D, Yun X, Yang Q, Huang X. An Inter-Ethnic Comparison Study of Ziprasidone Plasma Levels, Dosage and Clinical Response in Patients with Schizophrenia. Psychiatry Investig 2017; 14:360-367. [PMID: 28539955 PMCID: PMC5440439 DOI: 10.4306/pi.2017.14.3.360] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/31/2015] [Revised: 04/14/2016] [Accepted: 05/25/2016] [Indexed: 12/15/2022] Open
Abstract
OBJECTIVE The aim of this study was to investigate ziprasidone plasma concentration, daily dose and clinical efficacy and safety in Han Chinese and Mongolian patients with first-episode schizophrenia. METHODS A total of 123 inpatients affected by schizophrenia were recruited from the Mental Health Center of Inner Mongolia in China. Ziprasidone plasma concentration, clinical efficacy and side effects were systematically evaluated at baseline, and at 1, 2, 4, and 6 weeks. Metabolic measures such as changes in weight, body mass index (BMI), fasting blood glucose (FBG), triglycerides, and cholesterol, were also recorded. RESULTS 90 patients completed the study. Compared with Han patients, on average, Mongolian patients received a significantly higher ziprasidone dosage for adequate symptom control during the 6-week period and had a lower plasma concentration-to-dose ratio. The Mongolian patients also experienced greater increases in weight and BMI. No significant differences between the two ethnic groups were found in the rate of reduction in the Positive and Negative Syndrome Scale (PANSS) score, Treatment Emergent Symptom Scale (TESS) total score, FBG, triglycerides, cholesterol or Q-Tc interval. CONCLUSION Compared to Han Chinese patients, Mongolian patients appeared to have increased ziprasidone clearance and require higher doses to achieve effective treatment for schizophrenia.
Collapse
Affiliation(s)
- Dongsheng Lv
- Department of Psychiatry, Mental Health Center of Inner Mongolia, Inner Mongolia, Hohhot, China
- Department of Psychiatry, Second Xiangya Hospital of Central South University, Changsha, China
| | - Meirong Zhao
- Department of Psychiatry, Mental Health Center of Inner Mongolia, Inner Mongolia, Hohhot, China
- Department of Psychiatry, the First Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia, Hohhot, China
| | - Lixia Chen
- Department of Psychiatry, Mental Health Center of Inner Mongolia, Inner Mongolia, Hohhot, China
| | - Dongsheng Yu
- Department of Psychiatry, Mental Health Center of Inner Mongolia, Inner Mongolia, Hohhot, China
| | - Xiaobin Yun
- Department of Psychiatry, Mental Health Center of Inner Mongolia, Inner Mongolia, Hohhot, China
| | - Qing Yang
- Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA
| | - Xiaojun Huang
- Department of Psychiatry, Second Xiangya Hospital of Central South University, Changsha, China
| |
Collapse
|
7
|
Hall CA, Simon KM, Lenze EJ, Dew MA, Begley A, Butters MA, Blumberger DM, Stack JA, Mulsant B, Reynolds CF. Depression Remission Rates Among Older Black and White Adults: Analyses From the IRL-GREY Trial. Psychiatr Serv 2015; 66:1303-11. [PMID: 26278231 PMCID: PMC4666813 DOI: 10.1176/appi.ps.201400480] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
OBJECTIVE This study explored whether older black and white adults with major depressive disorder differed in rates of remission or attrition during open-label treatment with venlafaxine and supportive care. METHODS A total of 47 black (10%) and 412 white (90%) adults age ≥60 were treated with open-label venlafaxine extended-release (≤300 mg per day) for 12-14 weeks during the initial phase of an multisite, randomized, placebo-controlled augmentation trial. Participants were help-seeking older adults with nonpsychotic major depressive disorder (single or recurrent episode) referred from specialty clinics, primary care practices, advertisements, and research programs. Remission was defined as a Montgomery-Asberg Depression Rating Scale score of ≤10 for two consecutive assessments at the end of 12 weeks. Kaplan-Meier curves displayed time to dropout and time to initial remission. Cox proportional hazards models assessed differences in attrition and remission rates. RESULTS Black participants had greater baseline general medical comorbidity, worse physical health-related quality of life, and poorer cognitive function than white participants. White participants were more likely to have received an adequate trial of antidepressant and psychotherapy before study entry. Baseline depression severity, depression duration, age at onset, and recurrence history did not differ between groups. The groups had similar final doses of venlafaxine and similar rates of attrition and remission. Side-effect profiles were comparable between the groups. CONCLUSIONS Despite greater medical comorbidity, lower cognitive function, and less adequate prior exposure to antidepressant treatment and psychotherapy, black participants were no more likely to discontinue antidepressant pharmacotherapy and experienced a rate of remission comparable to white participants.
Collapse
Affiliation(s)
- Charles A Hall
- Dr. Hall, Dr. Dew, Ms. Begley, Dr. Butters, Ms. Stack, and Dr. Reynolds are with the Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Dr. Simon is also with the Department of Psychiatry, Morehouse University School of Medicine, Atlanta. Ms. Begley and Ms. Stack are also with the NIMH Center for Late Life Depression Prevention and Treatment, University of Pittsburgh. Dr. Lenze is with the Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri. Dr. Blumberger and Dr. Mulsant are with the Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. Send correspondence to Dr. Reynolds (e-mail: )
| | - Kevin M Simon
- Dr. Hall, Dr. Dew, Ms. Begley, Dr. Butters, Ms. Stack, and Dr. Reynolds are with the Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Dr. Simon is also with the Department of Psychiatry, Morehouse University School of Medicine, Atlanta. Ms. Begley and Ms. Stack are also with the NIMH Center for Late Life Depression Prevention and Treatment, University of Pittsburgh. Dr. Lenze is with the Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri. Dr. Blumberger and Dr. Mulsant are with the Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. Send correspondence to Dr. Reynolds (e-mail: )
| | - Eric J Lenze
- Dr. Hall, Dr. Dew, Ms. Begley, Dr. Butters, Ms. Stack, and Dr. Reynolds are with the Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Dr. Simon is also with the Department of Psychiatry, Morehouse University School of Medicine, Atlanta. Ms. Begley and Ms. Stack are also with the NIMH Center for Late Life Depression Prevention and Treatment, University of Pittsburgh. Dr. Lenze is with the Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri. Dr. Blumberger and Dr. Mulsant are with the Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. Send correspondence to Dr. Reynolds (e-mail: )
| | - Mary Amanda Dew
- Dr. Hall, Dr. Dew, Ms. Begley, Dr. Butters, Ms. Stack, and Dr. Reynolds are with the Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Dr. Simon is also with the Department of Psychiatry, Morehouse University School of Medicine, Atlanta. Ms. Begley and Ms. Stack are also with the NIMH Center for Late Life Depression Prevention and Treatment, University of Pittsburgh. Dr. Lenze is with the Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri. Dr. Blumberger and Dr. Mulsant are with the Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. Send correspondence to Dr. Reynolds (e-mail: )
| | - Amy Begley
- Dr. Hall, Dr. Dew, Ms. Begley, Dr. Butters, Ms. Stack, and Dr. Reynolds are with the Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Dr. Simon is also with the Department of Psychiatry, Morehouse University School of Medicine, Atlanta. Ms. Begley and Ms. Stack are also with the NIMH Center for Late Life Depression Prevention and Treatment, University of Pittsburgh. Dr. Lenze is with the Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri. Dr. Blumberger and Dr. Mulsant are with the Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. Send correspondence to Dr. Reynolds (e-mail: )
| | - Meryl A Butters
- Dr. Hall, Dr. Dew, Ms. Begley, Dr. Butters, Ms. Stack, and Dr. Reynolds are with the Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Dr. Simon is also with the Department of Psychiatry, Morehouse University School of Medicine, Atlanta. Ms. Begley and Ms. Stack are also with the NIMH Center for Late Life Depression Prevention and Treatment, University of Pittsburgh. Dr. Lenze is with the Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri. Dr. Blumberger and Dr. Mulsant are with the Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. Send correspondence to Dr. Reynolds (e-mail: )
| | - Daniel M Blumberger
- Dr. Hall, Dr. Dew, Ms. Begley, Dr. Butters, Ms. Stack, and Dr. Reynolds are with the Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Dr. Simon is also with the Department of Psychiatry, Morehouse University School of Medicine, Atlanta. Ms. Begley and Ms. Stack are also with the NIMH Center for Late Life Depression Prevention and Treatment, University of Pittsburgh. Dr. Lenze is with the Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri. Dr. Blumberger and Dr. Mulsant are with the Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. Send correspondence to Dr. Reynolds (e-mail: )
| | - Jacqueline A Stack
- Dr. Hall, Dr. Dew, Ms. Begley, Dr. Butters, Ms. Stack, and Dr. Reynolds are with the Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Dr. Simon is also with the Department of Psychiatry, Morehouse University School of Medicine, Atlanta. Ms. Begley and Ms. Stack are also with the NIMH Center for Late Life Depression Prevention and Treatment, University of Pittsburgh. Dr. Lenze is with the Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri. Dr. Blumberger and Dr. Mulsant are with the Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. Send correspondence to Dr. Reynolds (e-mail: )
| | - Benoit Mulsant
- Dr. Hall, Dr. Dew, Ms. Begley, Dr. Butters, Ms. Stack, and Dr. Reynolds are with the Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Dr. Simon is also with the Department of Psychiatry, Morehouse University School of Medicine, Atlanta. Ms. Begley and Ms. Stack are also with the NIMH Center for Late Life Depression Prevention and Treatment, University of Pittsburgh. Dr. Lenze is with the Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri. Dr. Blumberger and Dr. Mulsant are with the Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. Send correspondence to Dr. Reynolds (e-mail: )
| | - Charles F Reynolds
- Dr. Hall, Dr. Dew, Ms. Begley, Dr. Butters, Ms. Stack, and Dr. Reynolds are with the Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Dr. Simon is also with the Department of Psychiatry, Morehouse University School of Medicine, Atlanta. Ms. Begley and Ms. Stack are also with the NIMH Center for Late Life Depression Prevention and Treatment, University of Pittsburgh. Dr. Lenze is with the Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri. Dr. Blumberger and Dr. Mulsant are with the Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. Send correspondence to Dr. Reynolds (e-mail: )
| |
Collapse
|
8
|
Abstract
PURPOSE OF REVIEW This article reviews recent literature published over the period March 2012-August 2013 on antidepressant pharmacogenetics, with a focus on clinical translation and methodological challenges. RECENT FINDINGS Recently, various polymorphisms associated with differential antidepressant efficacy, tolerability, and safety have emerged in association studies, but mixed findings, limited effect sizes, and poor control of confounders have prevented findings translating to practice. Although promising steps have been made, empirically robust clinically translatable pharmacogenetic tests are not yet established. The complex neurobiology of major depressive disorder (MDD) together with the evolving understanding of genetic processes present research challenges for clinical translation. SUMMARY Early reports of clinical utility are published. The current evidence base for antidepressant pharmacogenetics is, however, not yet empirically robust enough to inform routine prescribing guidelines. Over the coming years, genetically guided versus unguided trials will help determine if antidepressant pharmacogenetics merits more widespread application.
Collapse
|
9
|
Specificity profile of venlafaxine and sertraline in major depression: metaregression of double-blind, randomized clinical trials. Int J Neuropsychopharmacol 2014; 17:1-8. [PMID: 23953038 DOI: 10.1017/s1461145713000746] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/23/2023] Open
Abstract
Despite the well-known efficacy of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) in the treatment of major depressive disorder, there is a lack of indications for each drug in different groups of patients. The aim of this study is to investigate the possible role of clinical sociodemographic factors as moderators of clinical response to venlafaxine (SNRI) and sertraline (SSRI). Research was performed on Medline and EMBASE for randomized control trials in English focused on sertraline and venlafaxine in the treatment of major depressive disorder and 59 studies were included. Clinical efficacy of each treatment was assessed on the basis of Hamilton Depressive Rating Scale and Montgomery-Asberg Depression Rating Scale. A metaregression analysis was performed to evaluate the role of clinical and sociodemographic factors as moderators of outcome, calculating the effect of each variable with the random-effects method. Gender, ethnicity and duration of depressive episode could have a role in prediction of clinical response to both antidepressants. Venlafaxine seems to have better effects in females and in Caucasian patients. Sertraline seems to be more efficacious in the treatment of females. Both drugs were more efficacious in patients who suffered a shorter episode of illness. Our results could represent an interesting point of view in the perspective of choosing the most suitable therapy based on clinical and social features for each patient. Metaregression is a retrospective analysis, based on the cumulative results of previous studies, so the lack of original data could represent the main limitation in this report and in the interpretation of the results obtained.
Collapse
|
10
|
Stewart SM, Simmons A, Habibpour E. Treatment of culturally diverse children and adolescents with depression. J Child Adolesc Psychopharmacol 2012; 22:72-9. [PMID: 22251021 DOI: 10.1089/cap.2011.0051] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
This article is written for the practitioners treating depression in ethnic minority youth. It will review the context in which services are delivered to these youth: Researchers have recognized persistent ethnic differences in terms of utilization of services and unmet need. Furthermore, when ethnic minority youth do receive pediatric mental health care, the services that they receive may differ from those given to White patients. The reasons for these discrepancies have been examined in numerous studies, and have included contextual variables (economics, availability, and accessibility of services), patient variables (differences in prevalence or manifestation of the disorder, cultural beliefs and attitudes, preferential use of alternative or informal services, health literacy, and adherence), and provider variables (referral bias and patient-provider communication). Information about the differences between White and minority youth in the pharmacodynamics and pharmacokinetics of the antidepressant response is still limited. There are significant challenges for developing evidence-based guidelines that inform practice with these youth, hinging on both the underrepresentation of ethnic minority groups in clinical trials, and the great variability in biological and cultural characteristics of individuals in ethnic minority categories. Awareness on the part of the practitioner of the cultural variables that influence help-seeking and ongoing utilization of mental health services may aid in the engagement, effective treatment, and retention of ethnic minority children and adolescents with depression. However, given the great heterogeneity that exists within any cultural grouping, clinicians will need to integrate information about cultural patterns with that obtained from the individual patient and family to inform optimal practices for each patient. This article is written to enhance awareness on the part of the practitioner as to the variables that influence psychiatric care for depression in culturally diverse youth. The mental health needs of minority youth are not well served: They are treated less frequently, and when they are treated, the services they receive are less frequently adequate. The reasons that have been proposed for the disparities in their care, particularly with regard to diagnosis and treatment for depression, will be reviewed. They include contextual factors (such as economics, insurance, and other variables affecting the availability of services) patient and family factors (such as prevalence, symptom presentation, and values and beliefs that influence whether patients are referred to and avail themselves of services), and provider factors (such as referral bias and patient-provider communication, which affect whether patients engage and stay in treatment). The implications for the practitioner treating ethnic minority youth with depression will be discussed. Culture, as used in this article, refers to the common values, beliefs, and social behaviors of individuals with a shared heritage. Some aspects of culture that are likely to influence service utilization include health beliefs, particularly regarding models of mental illness, and level of stigma toward mental health treatment, which are frequently shared by individuals in a cultural group. However, some caveats for the explanatory potential of "culture" should be kept in mind. Conventions for naming groups vary between investigators and over time (e.g., the restriction of the category "White" into "White NonHispanic," is quite recent). Although heterogeneity is assumed within a named cultural or racial group, the terms Hispanic, Asian, and African-American incorporate subgroups can be very different in linguistic, historical, and geographical ancestry (e.g., Stewart 2008 ), and each group incorporates individuals who may not share any components of their historical heritage. Even among those with historical ties, values, beliefs, and social behaviors can vary according to the extent to which they identify with the mainstream culture. Social class frequently creates a "culture" of its own, with individuals in the same social class across traditional cultural groupings sharing disparities in care, and many beliefs and values. Individuals are likely to belong to numerous "cultures," and may not share specific typical behaviors or beliefs with any of them.
Collapse
Affiliation(s)
- Sunita M Stewart
- Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390-8589, USA.
| | | | | |
Collapse
|
11
|
Abstract
Cultural psychiatry, as a subspecialty of psychiatry and thus medicine, has grown steadily and extensively in the 20th century, especially during the second part of this century. In this article, we look at the origins of cultural psychiatry; at its history through the centuries; at its role in the clinical, educational, and research domains; at its significance in today's conceptualization of the fields of psychiatry and mental health; and at its future perspectives within the realms of both medicine and psychiatry.
Collapse
|
12
|
Lesser IM, Myers HF, Lin KM, Bingham Mira C, Joseph NT, Olmos NT, Schettino J, Poland RE. Ethnic differences in antidepressant response: a prospective multi-site clinical trial. Depress Anxiety 2010; 27:56-62. [PMID: 19960492 PMCID: PMC3113513 DOI: 10.1002/da.20619] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
BACKGROUND Although depression is a highly prevalent condition that occurs in all ethnic groups, the influence of ethnicity on treatment response still remains unclear. METHODS A prospective 8-week, open-label clinical trial comparing the efficacy and side effects of citalopram (CIT) with dose escalation (20-60 mg/day) was performed in African-Americans and Caucasians with nonpsychotic major depression. The intent-to-treat sample consisted of 301 participants (169 African-Americans and 132 Caucasians). RESULTS Although African-Americans were more socially disadvantaged and had a more severe depression, outcomes between the groups were similar. Remission rates were approximately 50% in both groups and about 2/3 of participants met response criteria. Retention was greater than 75% in both groups, with no differences in dropout rate. There were no differences in the number of completers, number of visits made, final dose of CIT, or in side effect profiles. CONCLUSIONS These results confirm the growing body of evidence, including recent studies using measurement-based care, that patients from minority groups have outcomes that are similar to those of Caucasians. The provision of measurement-based care and encouragement of patient participation can reduce ethnic differences in response to treatment for depression.
Collapse
Affiliation(s)
- Ira M Lesser
- Department of Psychiatry, Harbor-UCLA Medical Center and the Los Angeles Biomedical Research Institute, Torrance, California, USA.
| | | | | | | | | | | | | | | |
Collapse
|
13
|
The impact of diabetes on depression treatment outcomes. Gen Hosp Psychiatry 2010; 32:33-41. [PMID: 20114126 DOI: 10.1016/j.genhosppsych.2009.07.009] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/21/2009] [Revised: 07/15/2009] [Accepted: 07/16/2009] [Indexed: 11/20/2022]
Abstract
BACKGROUND Individuals with diabetes mellitus (DM) are two to four times more likely to be diagnosed with major depressive disorder (MDD). However, few controlled studies have examined the impact of DM on the treatment of MDD. Understanding the effect of DM on depressed patients could provide valuable clinical information toward adjusting current treatment modalities to produce a more effective treatment for depressed patients with DM. METHODS This study was conducted using an evaluable sample of 2876 outpatient participants enrolled in the Sequenced Treatment Alternatives to Relieve Depression study. Sociodemographic and clinical characteristics and treatment characteristics with the selective serotonin reuptake inhibitor (SSRI) citalopram, as well as remission rates for MDD and time to remission, were compared between participants with DM and participants without DM. RESULTS The odds of remission were lower in participants with DM than in those without DM prior to adjustment [odds ratio (OR)=0.68; 95% confidence interval (95% CI)=(0.49, 0.94); P=.0184]. These differences were no longer present after adjustment [OR=0.92; 95% CI=(0.64, 1.32); P=.6399]. Participants with DM reported fewer side effects than participants without DM despite similar dosing. CONCLUSIONS Depressed patients with DM and depressed patients without DM appear to have similar rates of MDD remission, indicating that a diagnosis of DM per se has no impact on MDD remission. The findings of fewer side effects and psychiatric serious adverse events in participants with DM imply that depressed patients with DM may be excellent candidates for more aggressive SSRI dosing. This lower prevalence of side effects reported by depressed participants with DM warrants further exploration.
Collapse
|
14
|
Abstract
Ethnicity is reported to be an important, but often ignored factor in psychopharmacology. However, recent advances in molecular biology and the vision of 'personalised medicine' have spurred a debate on the role of ethnicity in this field. This paper reviews literature on the role of race and ethnicity in psychopharmacology. Despite considerable controversy on what the concepts of ethnicity and race actually measure, they are considered as important proxies for a person's culture, diet, beliefs, health behaviours and societal attitudes. Research has shown ethnic differences in the clinical presentation, treatment, clinical response and outcome of mental illnesses. A number of ethnically specific variations have been found in the genetic and non-genetic mechanisms affecting pharmacokinetics and dynamics of psychotropic drugs, which might underlie the previously mentioned differences in drug use and response across ethnicities. Although some of these ethnic differences could be partially explained by genetic factors, a number of ethnically based variables like culture, diet and societal attitudes could potentially have a significant, but as yet unquantified influence as well. Future research needs to address the problems with defining and accurately measuring 'ethnicity', as well as focus upon conducting studies that could guide treatments for people from diverse backgrounds.
Collapse
Affiliation(s)
- Ib Chaudhry
- School of Medicine, University of Manchester, UK.
| | | | | | | |
Collapse
|
15
|
Damush TM, Jia H, Ried LD, Qin H, Cameon R, Plue L, Williams LS. Case-finding algorithm for post-stroke depression in the veterans health administration. Int J Geriatr Psychiatry 2008; 23:517-22. [PMID: 18000947 DOI: 10.1002/gps.1930] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
OBJECTIVES Post-stroke depression (PSD) is prevalent, often undiagnosed, and undertreated. The accuracy of detecting patients with post-stroke depression in administrative databases has not been examined.The objective was to validate a case-finding algorithm for post-stroke depression (PSD) among veteran stroke survivors. METHODS We conducted a retrospective cohort study of veterans admitted to two local VHA facilities for an inpatient episode of care for acute ischemic stroke. Our cohort included all patients from two medical centers who were identified in the fiscal year (FY) 2001 VHA inpatient database using high specificity stroke ICD-9 codes. FY 2002 VHA and Medicare inpatient, outpatient, and pharmacy data were used to examine the patients' 12-month PSD status by using ICD-9 depression codes and antidepressant use. We assessed our accuracy about patients' PSD from the administrative databases through standardized chart reviews. RESULTS Of our 185 subject cohort, 50 (27%) were identified as having PSD. The most sensitive case-finding algorithm for PSD included having an ICD-9 code diagnosis for depression or receiving a prescription for an approved-dosage of antidepressant medication. However, the algorithm of receiving an ICD-9 code for primary or secondary diagnoses of depression revealed the largest positive predictive value. CONCLUSIONS A case-finding algorithm using outpatient ICD-9 codes or medication was the most sensitive in identifying cases of PSD. The use of ICD-9 codes alone may be adequate for characterizing a cohort with PSD. Intention for use should be considered when choosing an algorithm to detect PSD.
Collapse
Affiliation(s)
- Teresa M Damush
- The Stroke QUERI Center, Richard L. Roudebush VAMC HSR&D, Indianapolis, IN 46202, USA.
| | | | | | | | | | | | | |
Collapse
|
16
|
Yeung A, Overstreet KM, Albert EV. Current practices in depression care. THE JOURNAL OF CONTINUING EDUCATION IN THE HEALTH PROFESSIONS 2007; 27 Suppl 1:S9-S17. [PMID: 18085581 DOI: 10.1002/chp.130] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
Despite improved awareness among the medical community concerning common mental health disorders, the high prevalence of depression in the United States remains unchanged and has been compounded by increasing evidence of gaps in mental health care for ethnic and racial minorities. Thus, there is a strong need for the timely creation of comprehensive educational initiatives aimed at improving the quality of care provided by mental health professionals and primary care physicians. Fundamental to this process is the examination of current treatment standards, as well as identification of practices that require improved physician education. Consistent use of appropriate screening tools, diagnostic accuracy and timeliness, continual assessment of illness severity, adherence to practice guidelines, and individualized patient care need heightened attention to improve outcomes. This article describes the most prevalent types of depression and summarizes current practices in depression care, with an emphasis on treatment standards and opportunities for improved performance.
Collapse
Affiliation(s)
- Albert Yeung
- Depression Clinical & Research Program, Massachusetts General Hospital, 50 Staniford Street, Suite 401, Boston, MA 02114, USA.
| | | | | |
Collapse
|
17
|
Genetic variation, classification and 'race'. Nat Genet 2004; 36:S28-33. [PMID: 15508000 DOI: 10.1038/ng1435] [Citation(s) in RCA: 293] [Impact Index Per Article: 14.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2004] [Accepted: 09/08/2004] [Indexed: 01/06/2023]
Abstract
New genetic data has enabled scientists to re-examine the relationship between human genetic variation and 'race'. We review the results of genetic analyses that show that human genetic variation is geographically structured, in accord with historical patterns of gene flow and genetic drift. Analysis of many loci now yields reasonably accurate estimates of genetic similarity among individuals, rather than populations. Clustering of individuals is correlated with geographic origin or ancestry. These clusters are also correlated with some traditional concepts of race, but the correlations are imperfect because genetic variation tends to be distributed in a continuous, overlapping fashion among populations. Therefore, ancestry, or even race, may in some cases prove useful in the biomedical setting, but direct assessment of disease-related genetic variation will ultimately yield more accurate and beneficial information.
Collapse
|
18
|
Catalano M. Functionally gene-linked polymorphic regions and genetically controlled neurotransmitters metabolism. Eur Neuropsychopharmacol 2001; 11:431-9. [PMID: 11704420 DOI: 10.1016/s0924-977x(01)00120-1] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
In clinical psychopharmacology, the existence of marked inter-individual differences in both outcome and side effects is a common observation. Consequently, pharmacogenetics has also gained an increasing interest in psychiatry. Recent exciting findings seem to suggest that the growing interest in regulatory regions of candidate genes and neurotransmitters metabolism, together with the application of sophisticated molecular approaches, may offer new opportunities in neuropsychopharmacology. Indeed, quantitative variation of gene expression and/or of neurotransmitters metabolism could better explain both psychopathology and clinical response to psychotropic drugs. Three functional polymorphisms, and their possible relationship with clinical variables, are discussed. The first is the 44-bp insertion/deletion reported in the promoter region of the serotonin transporter gene. A functional repeat polymorphism in the promoter region of the gene encoding for the enzyme monoamine oxidase A represents the second example. The last is a functional polymorphism within the coding region of the gene encoding for the enzyme catechol-O-methyltransferase
Collapse
Affiliation(s)
- M Catalano
- IRCCS, H. San Raffaele, DSNP, Milan, Italy
| |
Collapse
|
19
|
Poland RE, Rao U, Lutchmansingh P, McCracken JT, Lesser IM, Edwards C, Ott GE, Lin KM. REM sleep in depression is influenced by ethnicity. Psychiatry Res 1999; 88:95-105. [PMID: 10622346 DOI: 10.1016/s0165-1781(99)00080-3] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The influence of ethnicity on the manifestation of EEG sleep changes in depression was studied in 95 patients (21 African-Americans [AA], 17 Asians [AS], 37 Caucasians [C] and 20 Hispanics [H]) with unipolar major depression. Subjects were studied twice for 2 consecutive nights. On the second night of each 2-night session, placebo or scopolamine (1.5 microg/kg, IM, at 23.00 h) was administered. On the baseline (placebo) night, sleep architecture, sleep continuity and rapid eye movement (REM) sleep variables were generally comparable among the groups. However, REM sleep was less in AA and AS subjects than in C and H subjects. Furthermore, the distribution of REM sleep over the course of the night in AA and AS subjects differed significantly from that in the C and H groups. Although scopolamine significantly affected sleep continuity and REM sleep measures, no significant differential effects of scopolamine were observed. Because many antidepressants suppress REM sleep, the differences in baseline REM sleep observed might be related to the greater sensitivity of some ethnic-minority depressed patients to pharmacotherapy.
Collapse
Affiliation(s)
- R E Poland
- Department of Psychiatry, Harbor-UCLA Medical Center, Torrance, CA 90509, USA.
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Affiliation(s)
- M Catalano
- Istituto di Ricovero e Cura a Carattere Scientifico H San Raffaele, DSNP, Milan, Italy.
| |
Collapse
|
21
|
Abstract
Ethnic differences in psychopharmacological treatment have received much attention in the last two decades. Most of the research efforts conducted so far in the field of ethnopsychopharmacology have focused on comparative responses to neuroleptics and lithium between white and Asian-American patients, and on comparative responses to tricyclic antidepressants among white, African-American and Hispanic patients. In this article we focus on the response to neuroleptic treatment among white, African-American and Hispanic patients suffering from schizophrenia. Our findings suggest that Hispanic patients need lower doses of neuroleptics than white or African-American patients to attain a similar response in the treatment of schizophrenia. Additionally, our study suggests that, if weight is taken to consideration, African-American patients need the same dose of neuroleptics as do white patients in order to attain a similar response in the treatment of schizophrenia. Further studies are suggested to confirm our findings.
Collapse
Affiliation(s)
- P Ruiz
- Department of Psychiatry and Behavioral Sciences, University of Texas Medical School at Houston, USA
| | | | | | | |
Collapse
|